Drug Formulation - Search News

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine® ...

Aspire Biopharma Holdings, Inc.: Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine.Meclizine was the top-prescribed antiemetic/a ...

The Manila Times

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting

NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research ...

pharmaphorum

Lundbeck preps phase 3 for migraine prevention drug

Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to ...

24/7 Wall St.

Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

Fierce Pharma

AbbVie mounts fresh IRA legal challenge over Botox's inclusion in latest drug pricing negotiations list

In response to last month’s list of the 15 drugs chosen by the Centers for Medicare & Medicaid Services (CMS) for upcoming ...

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam – Generic Xanax(R) – for Rapid Anxiety Relief

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

BioNxt Solutions Inc.: BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran ®, was the 53rd most commonly ...

Medscape

Show inaccessible results